Publications in DiVA – Angelica Loskog

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Part of Journal of Translational Medicine, 2023.

DOI for Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models Download full text (pdf) of Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

The signaling and the metabolic differences of various CAR T cell designs

Razavi, Azadeh Sadat; Loskog, Angelica S.; Razi, Sepideh; Rezaei, Nima

Part of International Immunopharmacology, 2023.

DOI for The signaling and the metabolic differences of various CAR T cell designs

Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis

Hellström, Vivan; Tufveson, Gunnar; Loskog, Angelica; Bengtsson, Mats et al.

Part of PLOS ONE, 2022.

DOI for Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis Download full text (pdf) of Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Part of MOLECULAR THERAPY-ONCOLYTICS, p. 429-442, 2022.

DOI for Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition Download full text (pdf) of Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

Sjöholm, Therese; Korenyushkin, Alexander; Gammelgård, Gustav; Sarén, Tina et al.

Part of Cancer Imaging, 2022.

DOI for Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy Download full text (pdf) of Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Mansoori, Sharmineh; Fryknäs, Mårten; Alvfors, Carina; Loskog, Angelica et al.

Part of Scientific Reports, 2021.

DOI for A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer Download full text (pdf) of A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up

Saellstrom, Sara; Sadeghi, Arian; Eriksson, Emma; Segall, Thomas et al.

Part of Frontiers in Veterinary Science, 2021.

DOI for Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up Download full text (pdf) of Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Wenthe, Jessica; Naseri, Sedigheh; Labani-Motlagh, Alireza; Enblad, Gunilla et al.

Part of Cancer Immunology and Immunotherapy, p. 2851-2865, 2021.

DOI for Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy Download full text (pdf) of Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Irenaeus, Sandra; Hellström, Vivan; Wenthe, Jessica; Krause, Johan et al.

Part of Cancer Gene Therapy, p. 1188-1197, 2021.

DOI for Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes

Labani-Motlagh, Alireza; Naseri, Sedigheh; Wenthe, Jessica; Eriksson, Emma et al.

Part of MOLECULAR THERAPY-ONCOLYTICS, p. 508-518, 2021.

DOI for Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes Download full text (pdf) of Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Jernberg Wiklund, Helena et al.

Part of Cancer Gene Therapy, p. 948-959, 2020.

DOI for Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40 Download full text (pdf) of Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Andersson, Claes; Selvin, Tove; Blom, Kristin; Rubin, Jenny et al.

Part of Scientific Reports, 2020.

DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.

Rowinsky, Eric K; Paner, Agne; Berdeja, Jesus G; Paba-Prada, Claudia et al.

Part of Investigational new drugs, p. 1448-1453, 2020.

DOI for Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

Labani-Motlagh, Alireza; Ashja-Mahdavi, Mehrnoush; Loskog, Angelica S.

Part of Frontiers in Immunology, 2020.

DOI for The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses Download full text (pdf) of The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients

Amini, Rose-Marie; Enblad, Gunilla; Hollander, Peter; Laszlo, S. et al.

Part of BMC Cancer, 2019.

DOI for Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients Download full text (pdf) of Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

Schiza, Aglaia; Irenaeus, Sandra; Ortiz-Nieto, Francisco; Loskog, Angelica S. et al.

Part of Scientific Reports, 2019.

DOI for Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients Download full text (pdf) of Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Part of Journal of Immunology, p. 787-798, 2019.

DOI for IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Blom, Kristin; Rubin, Jenny; Berglund, Malin; Jarvius, Malin et al.

Part of BMC Research Notes, 2019.

DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Enblad, Gunilla; Karlsson, Hannah; Gammelgård, Gustav; Wenthe, Jessica et al.

Part of Clinical Cancer Research, p. 6185-6194, 2018.

DOI for A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

Hollander, Peter; Rostgaard, Klaus; Ekström-Smedby, Karin; Molin, Daniel et al.

Part of European Journal of Haematology, p. 88-97, 2018.

DOI for An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome Download full text (pdf) of An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

Hoffmann, Jean-Marc; Schubert, Maria-Luisa; Wang, Lei; Hueckelhoven, Angela et al.

Part of Frontiers in Immunology, 2018.

DOI for Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients Download full text (pdf) of Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

Immunostimulatory gene therapy enhances PD-1 blockade antibody therapy in experimental lung cancer

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Loskog, Angelica S.

Part of CANCER IMMUNOLOGY RESEARCH, 2018.

DOI for Immunostimulatory gene therapy enhances PD-1 blockade antibody therapy in experimental lung cancer

Activating CD40 While Inhibiting IL6R Induces Cytokine Production without PDL1 Upregulation in DCs

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Part of Molecular Therapy, p. 54-54, 2017.

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Eriksson, Emma; Moreno, R; Milenova, I. Yoanna; Liljenfeldt, L et al.

Part of Gene Therapy, p. 92-103, 2017.

DOI for Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment Download full text (pdf) of Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Svensson, Emma et al.

Part of Journal of Translational Medicine, 2017.

DOI for Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients Download full text (pdf) of Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Eriksson, Emma et al.

Part of Scandinavian Journal of Immunology, p. 337-337, 2017.

An oncolytic virus targeting desmoplasia and immune activation in pancreatic cancer

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Part of Scandinavian Journal of Immunology, p. 335-335, 2017.

Distinct phenotype of CD19-specific CAR T cells generated from healthy donor vs. patient lymphocytes using either IL-7/IL-15 or IL-2

Hoffmann, J. -M; Stock, S.; Sellner, L.; Hueckelhoven, A. et al.

Part of Oncology Research and Treatment, p. 213-213, 2017.

Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

Hellström, Vivan; Tufveson, Gunnar; Wallgren, AnnaCarin; Loskog, Angelica et al.

Part of American Journal of Transplantation, p. 472-472, 2017.

DOI for Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

Immunological biomarkers correlate to survival in CAR19-treated patients

Lövgren, Tanja; Wenthe, Jessica; Karlsson, S. C. Hannah; Gammelgård, Gustav et al.

Part of Scandinavian Journal of Immunology, p. 337-337, 2017.

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Irenaeus, Sandra; Schiza, Aglaia; Mangsbo, Sara M.; Wenthe, Jessica et al.

Part of OncoTarget, p. 78573-78587, 2017.

DOI for Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients Download full text (pdf) of Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Low il-2 concentration favors generation of early memory t cells over terminal eefectors during car t-cell expansion

Luostarinen, A.; Kaartinen, T.; Maliniernii, P.; Keto, J. et al.

Part of Cytotherapy, p. S8-S8, 2017.

DOI for Low il-2 concentration favors generation of early memory t cells over terminal eefectors during car t-cell expansion

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Kaartinen, Tanja; Luostarinen, Annu; Maliniemi, Pilvi; Keto, Joni et al.

Part of Cytotherapy, p. 689-702, 2017.

DOI for Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion Download full text (pdf) of Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer

Yu, Di; Leja, Justyna; Loskog, Angelica S.; Hellman, Per et al.

Part of Neuroendocrinology, p. 54-66, 2017.

DOI for Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Svensson, Emma; Milenova, Ioanna; Wenthe, Jessica; Ståhle, Magnus et al.

Part of Clinical Cancer Research, p. 5846-5857, 2017.

DOI for Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Blom, Kristin; Senkowski, Wojciech; Jarvius, Malin; Berglund, Malin et al.

Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017.

DOI for The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

A Clinical Trial Using Third Generation CD19 Targeting CAR T Cells for Relapsed Lymphoma and Leukemia

Enblad, Gunilla; Karlsson, Hannah; Wenthe, Jessica; Wikström, Kristina I. et al.

Part of Molecular Therapy, p. S295-S296, 2016.

A Novel Oncolytic Adenovirus Expressing Tumor Microenvironment Stimulators to Evoke and Facilitate Anti-Tumor Immune Responses

Wenthe, Jessica; Eriksson, Emma; Milenova, Ioanna; Moreno, Rafael et al.

Part of Molecular Therapy, p. S206-S206, 2016.

An Oncolytic Adenovirus Gene Therapy Targeting Both Tumor Cell Survival and Desmoplasia in Pancreatic Cancer

Milenova, Ioanna; Eriksson, Emma; Moreno, Rafael; Alemany, Ramon et al.

Part of Molecular Therapy, p. S262-S262, 2016.

CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia: report from the Swedish phase Ulla trial

Enblad, Gunilla; Karlsson, Hannah; Wikström, Kristina I.; Essand, Magnus et al.

Part of CANCER IMMUNOLOGY RESEARCH, 2016.

DOI for CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia: report from the Swedish phase Ulla trial

Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Eriksson, Emma; Wenthe, Jessica; Irenaeus, Sandra; Loskog, Angelica et al.

Part of Journal of Translational Medicine, 2016.

DOI for Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer Download full text (pdf) of Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Part of British Journal of Cancer, p. 872-880, 2016.

DOI for Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, H. et al.

Part of Haematologica, p. 730-730, 2016.

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Part of Leukemia research, p. 95-103, 2016.

DOI for Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Prognostic Implications Of An Active, Innate Or Anergic Immune Response In The Hodgkin Lymphoma Tumor Microenvironment

Hollander, Peter; Rostgaard, K.; Smedby, K. E.; Molin, Daniel et al.

Part of Haematologica, p. 3-3, 2016.

T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells

Hoffmann, J. -M; Gern, U.; Wang, L.; Kleist, C. et al.

Part of Oncology Research and Treatment, p. 136-136, 2016.

DOI for T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells

CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

Enblad, Gunilla; Karlsson, Hannah; Loskog, Angelica S. I.

Part of Human Gene Therapy, p. 498-505, 2015.

DOI for CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

CD40L and 4-1BBL immunostimulating gene therapy reduces myeloid-derived suppressor cells (MDSCs) while promoting T and NK cell activation

Svensson, Emma; Wenthe, Jessica; Milenova, I. Yoanna; Moreno, R. et al.

Part of Human Gene Therapy, p. A53-A53, 2015.

CD40L/4-1BBL-expressing oncolytic adenovirus (LOAd703) stimulates human dendritic cell production of Th1 cytokines and antigen-specific T cells

Svensson, Emma; Milenova, I. Yoanna; Moreno, R.; Alemany, R. et al.

Part of Human Gene Therapy, p. A58-A59, 2015.

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

Karlsson, Hannah; Svensson, Emma; Gigg, Camilla; Jarvius, Malin et al.

Part of PLOS ONE, 2015.

DOI for Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors Download full text (pdf) of Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles

Loskog, Angelica

Part of Viruses, p. 5780-5791, 2015.

DOI for Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles Download full text (pdf) of Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles

Immunotherapy with a CD40L/4-1BBL double-armed oncolytic adenovirus drives Th1 immunity and control tumor progression in a pancreas cancer model

Svensson, Emma; Milenova, Ioanna; Moreno, Rafael; Alemany, Ramon et al.

Part of Cancer Research, 2015.

DOI for Immunotherapy with a CD40L/4-1BBL double-armed oncolytic adenovirus drives Th1 immunity and control tumor progression in a pancreas cancer model

Increased TACE (Tumor necrosis factor-alpha +/--converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results from an ENEST1st Substudy

Sopper, Sieghart; Mustjoki, Satu; Loskog, Angelica; Gjertsen, Bjorn T. et al.

Part of Blood, 2015.

Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity

Rodriguez-Garcia, A.; Svensson, Emma; Gil-Hoyos, R.; Fajardo, C. A. et al.

Part of Gene Therapy, p. 596-601, 2015.

DOI for Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson, Lisa; Söderlund, Stina; Mangsbo, Sara; Hjorth-Hansen, Henrik et al.

Part of Molecular Cancer Therapeutics, p. 1181-1191, 2015.

DOI for The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial

Enblad, Gunilla; Karlsson, Hannah; Wikström, Kristina; Essand, Magnus et al.

Part of Blood, 2015.

VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation

Huang, Hua; Langenkamp, Elise; Georganaki, Maria; Loskog, Angelica et al.

Part of The FASEB Journal, p. 227-238, 2015.

DOI for VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation

AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Part of Molecular Therapy, p. S247-S247, 2014.

DOI for AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Antigen Signaling Enhances Proliferation and Cytotoxic Capacity of CD19-Targeting CD28/4-1BB CAR T Cells During Expansion Without Inducing Exhaustion

Karlsson, Hannah; Gigg, Camilla; Svensson, Emma; Larsson, Rolf et al.

Part of Molecular Therapy, p. S61-S61, 2014.

Assessing tissue damage in multiple sclerosis: a biomarker approach

Burman, Joachim; Zetterberg, H; Fransson, Moa; Loskog, Angelica SI. et al.

Part of Acta Neurologica Scandinavica, p. 81-89, 2014.

DOI for Assessing tissue damage in multiple sclerosis: a biomarker approach

CAR T Cells Express CD40L and Activates Human Dendritic Cells

Karlsson, Hannah; Gustafsson, Wictor; Olsson-Strömberg, Ulla; Savoldo, Barbara et al.

Part of Molecular Therapy, p. S61-S61, 2014.

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

Liljenfeldt, Lina; Dieterich, Lothar C.; Dimberg, Anna; Mangsbo, Sara M. et al.

Part of Cancer Gene Therapy, p. 95-102, 2014.

DOI for CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

CD62L Expression on T Cells is Decreased in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Predicts Response to Therapy with Frontline Nilotinib

Sopper, S.; Mustjoki, S.; Loskog, Angelica; Gjertsen, B. et al.

Part of Haematologica, p. 64-64, 2014.

Development of Gene Transfer Technology

Svensson, Emma; Moreno, R.; Milenova, Ioanna; Christiansson, Lisa et al.

Part of Human Gene Therapy, p. A3-A4, 2014.

Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand

Liljenfeldt, Lina; Gkirtzimanaki, Katerina; Vyrla, Dimitra; Svensson, Emma et al.

Part of Cancer Immunology and Immunotherapy, p. 273-282, 2014.

DOI for Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand

Immunostimulating Gene Therapy Using an Oncolytic Adenovirus Armed with CD40 Ligand Potently Kill Tumor Cells, Activates Dendritic Cells and Induces T Cell Responses

Svensson, Emma; Moreno, Rafael; Milenova, Ioanna; Christiansson, Lisa et al.

Part of Molecular Therapy, p. S253-S254, 2014.

Intranasal Delivery of CNS-Retargeted Human Mesenchymal Stromal Cells Prolongs Treatment Efficacy of Experimental Autoimmune Encephalomyelitis

Fransson, Moa; Piras, Elena; Wang, Hao; Burman, Joachim et al.

Part of Immunology, p. 431-441, 2014.

DOI for Intranasal Delivery of CNS-Retargeted Human Mesenchymal Stromal Cells Prolongs Treatment Efficacy of Experimental Autoimmune Encephalomyelitis

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Sandin, Linda C.; Eriksson, Fredrik; Ellmark, Peter; Loskog, Angelica S. I. et al.

Part of Oncoimmunology, p. e2761-, 2014.

DOI for Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Reduced Expression of CD62L Is Associated with Increased ADAM1 7 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Sopper, Sieghart; Mustjoki, Satu; Loskog, Angelica; Gjertsen, Bjorn T. et al.

Part of Blood, 2014.

The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica S I et al.

Part of Journal of Neuroimmunology, p. 153-159, 2014.

DOI for The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, Lisa; Mustjoki, Satu; Simonsson, Bengt; Olsson-Strömberg, Ulla et al.

Part of EuPA Open Proteomics, p. 37-47, 2014.

DOI for The use of multiplex platforms for absolute and relative protein quantification of clinical material

Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica et al.

Part of Journal of Neuroimmunology, p. 141-141, 2014.

DOI for Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis

AdCD40L immunostimulatory gene therapy shifts the MDSC- and macrophage profiles and promotes T cell infiltration in the tumor microenvironment

Liljenfeldt, Lina; Svensson, E.; Huang, H.; Dieterich, L. et al.

Part of Human Gene Therapy, p. A169-A169, 2013.

alpha B-Crystallin regulates expansion of CD11b(+)Gr-1(+) immature myeloid cells during tumor progression

Dieterich, Lothar C; Schiller, Petter; Huang, Hua; Wawrousek, Eric F et al.

Part of The FASEB Journal, p. 151-162, 2013.

DOI for alpha B-Crystallin regulates expansion of CD11b(+)Gr-1(+) immature myeloid cells during tumor progression

Enhanced proliferation and tyrosine kinase pathway engagement in 4-1BB domain-containing CAR T cells

Karlsson, H.; Svensson, E.; Lindqvist, C.; Hambardzumyan, K. et al.

Part of Human Gene Therapy, p. A163-A163, 2013.

Genetically engineered T cells for the treatment of cancer

Essand, Magnus; Loskog, Angelica S I

Part of Journal of Internal Medicine, p. 166-181, 2013.

DOI for Genetically engineered T cells for the treatment of cancer

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, Lisa; Söderlund, Stina; Svensson, Emma; Mustjoki, Satu et al.

Part of PLOS ONE, p. e55818-, 2013.

DOI for Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia Download full text (pdf) of Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Nya fotspår

Loskog, Angelica

Part of Skor är huvudsaken, p. 20-21, 2013.

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis

Burman, Joachim; Fransson, Moa; Tötterman, Thomas H.; Fagius, Jan et al.

Part of Immunology, p. 211-219, 2013.

DOI for T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis

Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma

Westberg, Sara; Sadeghi, Arian; Svensson, Emma; Segall, Thomas et al.

Part of Journal of immunotherapy (1997), p. 350-358, 2013.

DOI for Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma

AdCD40L: Crossing the Valley of Death?

Ullenhag, Gustav; Loskog, Angelica S I

Part of International Reviews of Immunology, p. 289-298, 2012.

DOI for AdCD40L: Crossing the Valley of Death?

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

Fransson, Moa; Piras, Elena; Burman, Joachim; Nilsson, Berith et al.

Part of Journal of Neuroinflammation, p. 112-, 2012.

DOI for CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery Download full text (pdf) of CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus

Diaconu, Iulia; Cerullo, Vincenzo; Hirvinen, Mari L M; Escutenaire, Sophie et al.

Part of Cancer Research, p. 2327-2338, 2012.

DOI for Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus

T Regulatory Cells in B-Cell Malignancy: Tumor Support or Kiss of Death?

Lindqvist, Camilla A; Loskog, Angelica Si

Part of Immunology, p. 255-260, 2012.

DOI for T Regulatory Cells in B-Cell Malignancy: Tumor Support or Kiss of Death?

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

Dias, J D; Hemminki, O; Diaconu, I; Hirvinen, M et al.

Part of Gene Therapy, p. 988-998, 2012.

DOI for Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Lindqvist, Camilla; Christiansson, Lisa; Thörn, Ingrid; Mangsbo, Sara et al.

Part of Immunology, p. 296-306, 2011.

DOI for Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

AdCD40L Immunogene Therapy for Bladder Carcinoma: The First Phase I/IIa Trial

Malmström, Per-Uno; Loskog, Angelica S. I.; Lindqvist, Camilla A.; Mangsbo, Sara M. et al.

Part of Clinical Cancer Research, p. 3279-3287, 2010.

DOI for AdCD40L Immunogene Therapy for Bladder Carcinoma: The First Phase I/IIa Trial

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

Mangsbo, Sara; Sandin, Linda; Anger, Kerstin; Korman, Alan et al.

Part of Journal of immunotherapy (1997), p. 225-235, 2010.

DOI for Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis

Fransson, Moa; Piras, Elena; Wang, H; Rasmussen Duprez, I et al.

Part of Human Gene Therapy, p. 1381-1381, 2010.

DOI for Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Lindqvist, Camilla A.; Christiansson, Lisa H.; Simonsson, Bengt; Enblad, Gunilla et al.

Part of Immunology, p. 371-376, 2010.

DOI for T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

T regulatory cells lacking CD25 are increased in MS during relapse

Fransson, Moa; Burman, Joachim; Lindqvist, Camilla; Atterby, Christina et al.

Part of Autoimmunity, p. 590-597, 2010.

DOI for T regulatory cells lacking CD25 are increased in MS during relapse

Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas

Vardouli, Lina; Lindqvist, Camilla; Vlahou, Katerina; Loskog, Angelica et al.

Part of Cancer Gene Therapy, p. 848-860, 2009.

DOI for Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas

Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition

Lindqvist, Camilla; Sandin, Linda; Fransson, Moa; Loskog, Angelica

Part of Journal of immunotherapy (1997), p. 785-792, 2009.

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

Vikman, Sofia; Sommaggio, Roberta; De La Torre, Manuel; Öberg, Kjell et al.

Part of Acta Oncologica, p. 391-400, 2009.

DOI for Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue Download full text (pdf) of Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

The Janus faces of CD40 in cancer

Loskog, Angelica; Eliopoulos, Aristides

Part of Seminars in Immunology, p. 301-307, 2009.

DOI for The Janus faces of CD40 in cancer

The T-cell pool is anergized in patients with multiple sclerosis in remission

Fransson, Moa; Liljenfeldt, Lina S.; Fagius, Jan; Tötterman, Thomas et al.

Part of Immunology, p. 92-101, 2009.

DOI for The T-cell pool is anergized in patients with multiple sclerosis in remission

CD40L-based cancer therapy: Expert commentary

Loskog, Angelica; Eliopoulos, Aris

Part of New Gene Therapy and Cancer Research, 2008.

CpG oligonucleotides demonstrate increased therapeutic efficacy compared to BCG in an aggressive orthotopic bladder cancer model

Ninalga, Christina; Mangsbo, Sara; Loskog, Angelica; Essand, Magnus et al.

Part of Journal of immunotherapy (1997), p. 34-42, 2008.

DOI for CpG oligonucleotides demonstrate increased therapeutic efficacy compared to BCG in an aggressive orthotopic bladder cancer model

CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity

Mangsbo, Sara M; Ninalga, Christina; Essand, Magnus; Loskog, Angelica et al.

Part of Journal of immunotherapy (1997), p. 34-42, 2008.

DOI for CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity

Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma

von Euler, Henrik; Sadeghi, Arian; Carlsson, Björn; Rivera, Patricio et al.

Part of Journal of immunotherapy (1997), p. 377-384, 2008.

DOI for Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma